Bill > SB0055

This bill amends existing Utah law to establish comprehensive regulations for stem cell therapy, particularly focusing on placental stem cell treatments. The bill requires healthcare providers performing stem cell therapies not yet approved by the FDA to provide patients with a prominent written notice explaining that the treatment lacks FDA approval, and to obtain a detailed signed consent form outlining the treatment's nature, potential results, alternative options, and possible risks. Healthcare providers must display this notice in their office and include it in any advertisements for stem cell therapy, using specific formatting requirements such as minimum font sizes. The bill defines stem cell therapy as treatment using afterbirth placental perinatal stem cells, explicitly excluding any treatments derived from fetal or embryonic tissue. Additionally, the law allows persons to supply human cells or tissues to healthcare providers, provided the provider commits to giving patients the required FDA approval notice. The bill includes exceptions for providers with FDA investigational drug approvals or those working under certified institutions. Any violation of these requirements is considered unprofessional conduct, and the bill is set to take effect on May 6, 2026.

Health and Social Services

https://le.utah.gov/~2026/bills/static/SB0055.html